Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.41 |
| ▸ | ANPEP | P15144 | 4/20 | 0.41 |
| ▸ | MMP1 | P03956 | 3/20 | 0.36 |
| ▸ | MMP3 | P08254 | 3/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | MMP7 | P09237 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201027 | 1.00 | MMP2 (0.41) | MMP2ANPEPMMP1MMP3MMP13 | |
| SCHEMBL27972041 | 0.88 | MMP2 (0.41) | MMP2ANPEPMMP1MMP3MMP13 | |
| SCHEMBL752424 | 0.83 | MAPK1 (0.36) | MMP1MMP3MMP13MMP7PTPN1 | |
| SCHEMBL18089593 | 0.81 | PTPN1 (0.51) | MMP2ANPEPMMP1MMP3MMP13 | |
| SCHEMBL2531159 | 0.81 | PTPN1 (0.51) | MMP2ANPEPMMP1MMP3MMP13 | |
| SCHEMBL2610760 | 0.81 | MMP2 (0.37) | MMP2ANPEPMMP1MMP3MMP13 | |
| SCHEMBL2619059 | 0.81 | MMP2 (0.37) | MMP2ANPEPMMP1MMP3MMP13 | |
| SCHEMBL206327 | 0.81 | PTPN1 (0.51) | MMP2ANPEPMMP1MMP3MMP13 | |
| SCHEMBL15083833 | 0.81 | MMP2 (0.57) | MMP2ANPEPCYP19A1BRD4PTPN1 | |
| SCHEMBL201253 | 0.81 | MMP2 (0.57) | MMP2ANPEPCYP19A1BRD4PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020225095-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-12 | — | — | WO | disclosed |